RT Journal Article
SR Electronic
T1 Initial Safety and Outcomes of Miriplatin plus Low-dose Epirubicin for Transarterial Chemoembolisation of Hepatocellular Carcinoma
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 5039
OP 5044
VO 32
IS 11
A1 JIN IWAZAWA
A1 NAOKO HASHIMOTO
A1 SHOICHI OHUE
A1 TAKASHI MITANI
YR 2012
UL http://ar.iiarjournals.org/content/32/11/5039.abstract
AB Aim: To evaluate the initial safety and efficacy of combination therapy using miriplatin plus low-dose epirubicin for transarterial chemoembolisation (TACE) of unresectable hepatocellular carcinoma (HCC). Patients and Methods: Patients who underwent TACE using miriplatin plus epirubicin (n=48) and control patients who underwent TACE using miriplatin-alone (n=51) were included in this study. Results: The objective response rate in the miriplatin plus epirubicin group (91%) was significantly higher than that in the miriplatin group (74%, p=0.024). Concomitant use of miriplatin and epirubicin was an independent factor associated with higher objective response rate (hazard ratio=0.18; p=0.012). Overall incidence adverse events was not significantly different between the miriplatin plus epirubicin group (50%) and the miriplatin group (49%, p=0.575). Conclusion: TACE using miriplatin plus low-dose epirubicin was associated with an increased objective response rate and comparable adverse effects compared to TACE using miriplatin-alone.